title: Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?
abstract: Dickkopf-1 (DKK1) is a secreted Wnt/β-catenin pathway antagonist involved in embryogenesis. It was first described 25 years ago for its function in head induction and limb morphogenesis. Since then, this protein has been widely studied in the context of active Wnt/β-catenin signalling during cellular differentiation and development. Dysregulation of DKK1 has been associated with bone pathologies and has now emerged as a potential biomarker of cancer progression and prognosis for several types of malignancies. Reducing the amount of circulating DKK1 may reveal a simple and efficient strategy to limit or reverse cancer growth. This review will provide an overview of the role of Dickkopf-1 in cancer and explore its potential use as a biomarker and therapeutic target.
authors.affiliation: CHU de Qu&#233;bec Research Center, 2705 Boulevard Laurier, RC-9800, Qu&#233;bec, QC G1V 4G2, Canada. melody.mazon@chudequebec.ulaval.ca.
authors.forename: Mélody
authors.initials: M
authors.lastname: Mazon
authors.affiliation: CHU de Qu&#233;bec Research Center, 2705 Boulevard Laurier, RC-9800, Qu&#233;bec, QC G1V 4G2, Canada. delphine.masi@chudequebec.ulaval.ca.
authors.forename: Delphine
authors.initials: D
authors.lastname: Masi
authors.affiliation: CHU de Qu&#233;bec Research Center, 2705 Boulevard Laurier, RC-9800, Qu&#233;bec, QC G1V 4G2, Canada. madeleine.carreau@crchul.ulaval.ca.|Department of Pediatrics, Universit&#233; Laval, Qu&#233;bec, QC G1V 0A6, Canada. madeleine.carreau@crchul.ulaval.ca.
authors.forename: Madeleine
authors.initials: M
authors.lastname: Carreau
keywords: DKK1; Dickkopf-1; Wnt/β-catenin signaling; biomarker; cancer therapeutics; tumour vaccine